01Approach to the Critical Patient/attcp56

Immediate stabilization

›Hemodynamic instability triggers

›SBP < 90 mmHg with symptomatic bradycardia

›IV access and fluid bolus if volume depleted

›Continuous cardiac monitoring

›Heart rate < 40 bpm while awake with symptoms

›Atropine 0.5 mg IV, repeat every 3-5 minutes to maximum 3 mg

›Transcutaneous pacing if atropine fails

›Recurrent syncope or syncope with injury

›Resuscitation bay placement

›Cardiology or electrophysiology consult

›Airway and perfusion assessment

›Mental status as cerebral perfusion surrogate

›Confusion or obtundation from hypoperfusion

›GCS trend monitoring

›Signs of end-organ hypoperfusion

›Oliguria

›Mottled skin

›Lactate elevation >= 2 mmol/l

›Reversible cause identification

›Medication review for offending agents

›Beta blockers

›Non-dihydropyridine calcium channel blockers

›Digoxin

›Antiarrhythmics (Class I and III)

›Metabolic screen

›Electrolytes including potassium

›Thyroid function

02History/hx90

Symptom characterization

›Cardinal symptoms of cerebral hypoperfusion

›Syncope

›Duration of loss of consciousness

›Injury sustained during episode

›Presyncope

›Lightheadedness or near-fainting

›Positional component

›Dizziness

›Relationship to exertion vs rest

›Recurrence frequency

›Additional cardiopulmonary symptoms

›Palpitations

›Rapid irregular episodes suggesting tachyarrhythmia component

›Termination pattern

›Dyspnea on exertion

›Exercise intolerance progression

›Chronotropic incompetence pattern

›Chest pain

›Anginal features

›Relationship to bradycardia episodes

›Neurologic and general symptoms

›Fatigue and weakness

›Chronic progressive course

›Functional decline

›Confusion or memory problems

›Recurrent cerebral hypoperfusion episodes

›Cognitive baseline vs acute change

›Falls

›Syncope-related falls

›Injury risk assessment

Symptom timing and triggers

›Temporal patterns

›Symptoms at rest vs exertion

›Rest bradycardia with symptoms suggests intrinsic disease

›Exertional limitation suggesting chronotropic incompetence

›Intermittent vs persistent symptoms

›Often subtle and difficult to capture

›Worsening over time with disease progression

›Nocturnal symptoms

›Sleep-related bradycardia

›OSA contribution

›Relationship to medications

›Recent medication changes

›New beta blocker or CCB initiation

›Antiarrhythmic addition

›Medication dose adjustments

›Digoxin level context

›Lithium toxicity context

Risk factors and past history

›Demographic and cardiovascular risk

›Age as strongest risk factor

›Incidence increases markedly with advancing age

›HR 1.52 per 5-year increment in population studies

›Hypertension

›HR 1.21 in population-based analysis

›Target organ involvement

›Prior myocardial infarction

›HR 1.54 in UK Biobank study

›Ischemic sinoatrial node disease

›Obesity and diabetes mellitus

›Independent risk factors

›Metabolic cardiovascular disease link

›Structural and infiltrative cardiac history

›Prior cardiac surgery

›Atrial septal defect repair

›Fontan, Mustard, Senning procedures

›Infiltrative disease

›Amyloidosis

›Sarcoidosis

›Hemochromatosis

›History of atrial fibrillation or flutter

›Tachy-brady syndrome in >= 50% of SSS patients

›Thromboembolic risk elevation

›Family and genetic history

›Ion channel disorders

›HCN4 mutations

›SCN5A mutations

›Sudden cardiac death in family

›Early pacemaker placement in relatives

›Congenital heart disease

Social and occupational history

›Athletic training history

›Physiologic bradycardia differentiation

›Well-trained athletes at rest

›Absence of symptoms distinguishes from pathologic

›Deconditioning vs pathologic change

›Driving and occupational hazards

›Syncope risk with driving

›Mandatory restriction until controlled

›Occupational machinery operation risk

›Tobacco and substance use

›Marijuana and sympatholytic effects

›Stimulant use and tachyarrhythmia component

03Physical Exam/exam69

Vital signs and hemodynamic assessment

›Heart rate assessment

›Resting bradycardia < 50 bpm

›Sinus bradycardia pattern

›Junctional escape pattern

›Heart rate response to activity

›Chronotropic incompetence if rate does not rise appropriately with exertion

›Maximum predicted HR failure

›Rhythm irregularity

›Grouped beating pattern suggesting sinoatrial exit block

›Abrupt transitions between fast and slow rates

›Blood pressure

›Orthostatic measurements

›SBP drop >= 20 mmHg or DBP >= 10 mmHg on standing

›Syncope correlation

›Baseline hypotension

›SBP < 90 mmHg threshold for instability

›End-organ hypoperfusion signs

›Respiratory rate and oximetry

›Dyspnea severity quantification

›Heart failure overlap

›Pulmonary congestion signs

Cardiovascular exam

›Auscultation

›Irregular rhythm detection

›Variable pause lengths

›Rate changes with position or activity

›S3 or S4 gallop

04Differential Diagnosis/ddx79

Bradyarrhythmia causes

›Intrinsic sinoatrial causes

›Sick sinus syndrome

›ICD-10 I49.5

›Sinus node dysfunction spectrum

›Physiologic sinus bradycardia

›Athletic training

›Absent symptoms of hypoperfusion

›Sinus arrest or block

›Electrolyte causes

›Ischemic causes

›AV conduction disease

›High-degree AV block

›Mobitz Type II

›Third-degree (complete) AV block

›May coexist with SSS

›Separate ECG differentiation required

›Dual-chamber pacing indication when coexistent

›Drug-induced bradycardia

›Reversible extrinsic cause

›Beta blockers

›Non-dihydropyridine CCBs (diltiazem, verapamil)

›Digoxin

›Class I antiarrhythmics (flecainide, propafenone)

›Class III antiarrhythmics (amiodarone, sotalol)

›Medication withdrawal often curative

›Monitor for rebound tachycardia

›Reassess underlying rhythm after washout

05Laboratory Tests/lt52

Core metabolic and thyroid assessment

›Electrolytes and renal function

›Serum potassium

›Hyperkalemia as reversible cause of bradycardia

›Hypokalemia in tachy-brady context

›Serum sodium, calcium, magnesium

›Electrolyte-driven arrhythmia exclusion

›Magnesium correction for arrhythmia stability

›Creatinine and eGFR

›Drug dosing adjustment (digoxin clearance)

›Contrast nephropathy planning for imaging

›Thyroid function tests

›TSH

›Hypothyroidism as reversible bradycardia cause

›Hyperthyroidism as tachyarrhythmia cause in tachy-brady

›Free T4 if TSH abnormal

›Degree of dysfunction quantification

›Treatment urgency determination

›Complete blood count

›Anemia as functional aggravator

›Hemoglobin threshold for transfusion consideration

›Volume status impact on cardiac output

›Leukocytosis suggesting infectious or inflammatory trigger

›Myocarditis or pericarditis consideration

›Endocarditis in appropriate context

Cardiac biomarkers and coagulation

›Cardiac troponin

›Acute myocardial infarction exclusion

06Diagnostic Tests/dt101

Scoring Systems

›No validated scoring system specific to SSS diagnosis

›Clinical diagnosis requires symptom-rhythm correlation

›Bradyarrhythmia documented during symptoms

›Absence of symptoms during documented arrhythmia does not exclude

›Severity stratification

›Mild: intermittent fatigue, asymptomatic bradycardia

›Moderate: presyncope, exercise intolerance, palpitations

›Severe: recurrent syncope, hemodynamic instability, heart failure

›CHA2DS2-VASc score for stroke risk in atrial fibrillation component

›Congestive heart failure (1 point)

›Hypertension (1 point)

›Age >= 75 years (2 points)

›Diabetes mellitus (1 point)

›Stroke or TIA history (2 points)

›Vascular disease (1 point)

›Age 65-74 years (1 point)

›Sex category female (1 point)

›Score >= 2 in males or >= 3 in females indicates anticoagulation

MRI

›Cardiac MRI indications in SSS

›Infiltrative cardiomyopathy characterization

›Late gadolinium enhancement for amyloidosis, sarcoidosis

›Myocarditis fibrosis mapping

›Structural heart disease workup

›Congenital anomalies pre-pacemaker planning

›Ventricular function quantification

›MRI compatibility with pacemakers

›MRI-conditional pacemaker systems required

›1.5 Tesla safety confirmation for most MRI-conditional devices

›3 Tesla imaging only with certified MRI-conditional systems

›Pre-implantation planning consideration

›Future MRI needs guide device selection

›Programmer availability during scan required

CT

›CT angiography in SSS evaluation

›Coronary CT angiography

›Ischemic sinoatrial node disease exclusion

›Right coronary artery territory assessment

›Structural and vascular causes

›Aortic pathology in appropriate clinical context

›Pulmonary embolism exclusion if tachycardia component

›CT chest for infiltrative disease

›Sarcoidosis pulmonary involvement

›Bilateral hilar lymphadenopathy

›Interstitial lung disease pattern

›Malignancy with cardiac infiltration

›Mediastinal mass assessment

›Pericardial effusion

Ultrasound

›Echocardiography

›Structural heart disease assessment

›Left ventricular ejection fraction

›Valvular disease identification

›Sinoatrial region and right atrium

›Right atrial size as marker of chronic atrial disease

›Thrombus exclusion before cardioversion in tachy-brady

›Diastolic dysfunction

›Heart failure with preserved ejection fraction

›Infiltrative pattern (restrictive physiology)

›Point-of-care ultrasound

›IVC collapsibility for volume status

›Fluid responsiveness assessment

›Hypotension management guidance

›Pericardial effusion

›Tamponade exclusion in hemodynamic compromise

›Myopericarditis workup

ECG

›Classic ECG findings in SSS

›Sinus bradycardia < 50 bpm

›Narrow complex with P wave preceding each QRS

›P axis 0-90 degrees confirming sinus origin

›Sinus pauses or sinus arrest

›Pause > 3 seconds while awake is clinically significant

›Absent P waves during pause

›Sinoatrial exit block

›Grouped beating pattern

›Dropped P waves without QRS changes

›Tachy-brady syndrome pattern

›Alternating rapid supraventricular tachycardia and bradycardia

›Atrial fibrillation most common tachyarrhythmia

›Chronotropic incompetence

›Failure to achieve 85% of maximum predicted HR during exercise

›Blunted rate response

›Dangerous patterns

›Prolonged asystolic pause after tachycardia termination

›High syncope risk

›Immediate pacing consideration

›Concurrent AV conduction disease

›Mobitz II or third-degree AV block

›Dual-chamber pacing indication

Ambulatory Monitoring

›Holter monitoring

›24-48 hour continuous recording

›Symptom-rhythm correlation in frequent symptoms

›Arrhythmia burden quantification

›Extended Holter up to 14 days

›Weekly or biweekly symptom frequency

›Patch monitor equivalent

›Event monitors and implantable loop recorders

›External event monitor

›Monthly symptom frequency

›Patient-activated recording

›Implantable cardiac monitor (loop recorder)

›Cryptogenic syncope with negative initial workup

›Monitoring up to 3 years

›ACEP Level B recommendation for unexplained recurrent syncope

07Disposition/dispo42

Admission criteria

›Criteria for hospital admission

›Hemodynamic instability

›SBP < 90 mmHg with symptomatic bradycardia

›Transcutaneous or transvenous pacing requirement

›Recurrent syncope

›High injury risk

›Unable to exclude life-threatening cause

›Anginal symptoms

›ACS cannot be excluded

›Ischemic sinoatrial disease concern

›Ventricular arrhythmias

›On monitoring during evaluation

›Structural heart disease coexisting

›New high-degree AV block on ECG

›Mobitz II or complete heart block

›Dual pathology workup

›ICU-level care indications

›Requirement for transcutaneous or transvenous pacing

›Continuous pacing threshold monitoring

›Complication risk (muscle pain, device malfunction)

›Hemodynamic instability requiring vasopressors

›Isoproterenol or dopamine infusion

›Intensive monitoring requirement

Observation and discharge criteria

›Observation indications

›Symptomatic bradycardia with stable vitals pending cardiology consultation

›Heart rate monitoring for 12-24 hours

08Treatment/t104

Acute management of symptomatic bradycardia

›Atropine

›Dose 0.5 mg IV

›Repeat every 3-5 minutes as needed

›Maximum cumulative dose 3 mg

›Indication: symptomatic bradycardia with hemodynamic compromise

›Class I recommendation per 2018 ACC/AHA/HRS Guideline

›May be ineffective post cardiac transplant (denervated heart)

›Ineffective for infranodal block

›May paradoxically worsen Mobitz II

›Caution when AV block coexists with SSS

›Transcutaneous pacing

›Indication: atropine failure or hemodynamic instability

›Pads anterior-posterior placement preferred

›Current titrated from low to achieve capture (50-200 mA)

›Rate setting 60-80 bpm typically

›Sedation and analgesia for patient comfort

›Confirm electrical and mechanical capture

Temporizing pharmacologic measures

›Isoproterenol

›IV infusion 2-10 mcg/minute

›Titrate to heart rate and hemodynamic response

›Avoid in active myocardial ischemia

›Indication: bridge to pacing when atropine ineffective

›Chronotropic and inotropic effects

›Short-term use only

›Dopamine

›IV infusion 5-20 mcg/kg/minute

›Chronotropic at higher doses

›Vasopressor effect at doses > 10 mcg/kg/minute

›Indication: bradycardia with hypotension

›Bridge to pacing

›Titrate to MAP >= 65 mmHg

›Aminophylline or theophylline

›Oral theophylline for patients declining pacemaker

›Phosphodiesterase inhibitor mechanism

›THEOPACE trial: reduced heart failure incidence vs pacemaker alone

›Not standard first-line

›SORT rating C evidence

›Short-term rate improvement demonstrated

Reversible cause treatment

›Medication discontinuation

›Beta blocker withdrawal

›Gradual taper to avoid rebound tachycardia if long-term use

›Monitor for symptom resolution over drug half-life

›Non-dihydropyridine CCB cessation

›Diltiazem half-life 3-4 hours

›Verapamil half-life 6-12 hours

›Digoxin dose reduction or discontinuation

›Repeat digoxin level in 6 hours after dose held

›Digoxin-specific Fab antibodies for severe toxicity

›Antiarrhythmic discontinuation

›Amiodarone: prolonged washout due to long half-life (40-55 days)

›Flecainide and propafenone: shorter washout

›Metabolic correction

›Hyperkalemia treatment

›Calcium gluconate 1 g IV for membrane stabilization

›Sodium bicarbonate, insulin-dextrose, kayexalate

›Hypothyroidism treatment

›Levothyroxine replacement

›Cautious initiation in elderly and cardiac disease

›Obstructive sleep apnea

›CPAP initiation may resolve nocturnal bradycardia

›Follow-up Holter monitoring after CPAP compliance

Permanent pacemaker therapy

›Indications for permanent pacing

›Symptomatic SSS with documented bradyarrhythmia correlation

›Class I indication per 2018 ACC/AHA/HRS Guideline

›Symptom-rhythm correlation is mandatory

›Chronotropic incompetence with symptoms limiting function

›Rate-responsive pacing programming required

›Sensor-based rate adaptation

›SSS with required long-term medications causing bradycardia

›Pacemaker enables safe continuation of needed drugs

›Class I indication

›Pacemaker mode selection

›Atrial-based pacing (AAI or DDD) preferred over VVI

›Lower incidence of atrial fibrillation and stroke with atrial-based pacing

›VVI only if chronic atrial fibrillation with no AV conduction

›Dual-chamber pacing (DDD) when AV conduction abnormalities present or anticipated

›Prevents pacemaker syndrome

›Physiologic AV synchrony maintained

›Rate-responsive pacing (DDDR or AAIR) for chronotropic incompetence

›Accelerometer or minute ventilation sensor

›Improved exercise capacity

›Clinical outcomes of pacemaker therapy

›Symptom improvement in majority of patients

›Significant improvement within days to weeks

›Quality of life improvement (Class I evidence)

›Pacemakers do not reduce mortality in SSS

›AFP/JACC evidence: symptom benefit without survival benefit

›Atrial fibrillation risk reduction with atrial-based pacing

›Thromboembolic risk

›Anticoagulation per AF guidelines if atrial fibrillation component

›CHA2DS2-VASc score guides decision

Tachy-brady management

›Antiarrhythmic and rate-control initiation order

›Pacemaker placement before antiarrhythmic or rate-control agents

›Antiarrhythmics worsen bradycardia component without pacemaker backup

›Class I recommendation per ACC/AHA/HRS Guideline

›Rate control for atrial fibrillation after pacemaker

›Beta blockers or non-dihydropyridine CCBs after pacemaker placement

›Target ventricular rate 60-80 bpm at rest

›Anticoagulation for atrial fibrillation

›CHA2DS2-VASc-guided anticoagulation

›Direct oral anticoagulants preferred over warfarin

›Apixaban 5 mg twice daily standard dose

›Rivaroxaban 20 mg once daily with evening meal

›Dabigatran 150 mg twice daily standard dose

09Special Populations/sp87

Pregnancy

›SSS in pregnancy

›Physiologic changes affecting assessment

›Heart rate increases 10-20 bpm in normal pregnancy

›Resting bradycardia less common physiologically

›Diagnosis approach

›ECG safe in pregnancy

›Holter monitoring safe and preferred for symptom correlation

›Echocardiography safe without radiation

›Risk stratification

›Symptomatic SSS with syncope is high-risk obstetric concern

›Multidisciplinary management with obstetrics and cardiology

›Treatment in pregnancy

›Atropine in acute setting

›Short-term use acceptable for acute symptomatic bradycardia

›Fetal tachycardia possible with maternal atropine

›Permanent pacemaker in pregnancy

›Indicated for symptomatic SSS with hemodynamic compromise

›Lead implantation guided by echocardiography to minimize fluoroscopy

›Fluoroscopy with abdominal shielding if unavoidable

›Medication safety

›Avoid antiarrhythmics in tachy-brady without pacemaker backup

›Beta blockers (atenolol avoided; metoprolol preferred if needed)

›Theophylline: generally avoided in pregnancy

Geriatric

›Age-related considerations

›SSS predominantly a disease of older adults

›Incidence increases markedly with age

›Fibrosis and degenerative change of sinoatrial node

›Atypical presentations

›Fatigue, confusion, and falls without classic syncope

›Cognitive decline mimicking dementia

›Functional decline as predominant symptom

›Polypharmacy risk

›Multiple offending medications common in elderly

›Beta blockers for hypertension or heart failure

›CCBs for hypertension

›Digoxin for heart failure or rate control

›Medication reconciliation essential

›Drug interactions between cardiac medications

›Renal clearance reduced, raising drug levels

›Pacemaker therapy in elderly

›Excellent symptom benefit even in very elderly patients

›MRI-conditional devices preferred for imaging flexibility

›Leadless pacemakers available for appropriate indications

›Anesthesia risk for device implantation

›Frailty assessment pre-procedure

›Minimized sedation strategies

›Fall and cognitive risk

›Syncope-related fall prevention

›Driving restriction until heart rate controlled

›Home safety assessment

›Anticoagulation in elderly with atrial fibrillation

›Bleeding risk vs thromboembolic risk balance

›HAS-BLED score consideration

›Direct oral anticoagulants preferred over warfarin in elderly

Pediatrics

›Causes of SSS in children

›Congenital structural heart disease

›Post-surgical SSS after atrial septal defect repair

›Fontan procedure, Mustard and Senning repairs

›Congenital sinoatrial node disease (HCN4, SCN5A mutations)

›Inflammatory and infectious causes

›Myocarditis

›Lyme carditis (Borrelia burgdorferi)

›Rheumatic heart disease

›Diagnosis in pediatric patients

›Resting heart rate norms vary by age

›Neonates: 100-160 bpm normal

›Infants: 80-140 bpm normal

›Adolescents: 60-100 bpm normal

›Symptoms may be subtle

›Poor feeding, irritability in infants

›Exercise intolerance, syncope in older children

›Genetic testing for channelopathies

›HCN4 mutation in familial sick sinus syndrome

›SCN5A overlap with long QT syndrome type 3

›Treatment in pediatric patients

›Atropine dose: 0.02 mg/kg IV

›Minimum dose 0.1 mg to avoid paradoxical bradycardia

›Maximum single dose 0.5 mg in children

›Permanent pacemaker in children

›2021 PACES guidelines: Class I for symptomatic SSS

›Epicardial pacing for small children (< 15 kg) or complex congenital heart disease

›Transvenous approach when vascular access allows

›Growth considerations for lead selection and redundancy

›Antiarrhythmic therapy for tachy-brady

›Only after pacemaker placement

›Pediatric weight-based dosing required

›Electrophysiology-guided management

10Background/b88

Epidemiology

›Incidence and prevalence

›Primary indication for 30-50% of pacemaker implantations in the United States

›Most common indication for permanent pacing globally

›Prevalence increases sharply with advancing age

›Population-based incidence data

›Incidence increases HR 1.52 per 5-year age increment (Jensen et al., JACC 2014)

›White race associated with higher incidence vs Black individuals (41% lower risk in Black individuals)

›Risk factor epidemiology

›Hypertension HR 1.21

›Diabetes mellitus as independent risk factor

›Obesity and higher BMI

›Prior myocardial infarction HR 1.54

›Right coronary artery occlusion most relevant

›UK Biobank data confirmation (Heart 2026)

›Elevated NT-proBNP and cystatin C as biomarker risk factors

›Right bundle branch block and longer QRS interval

›Prior cardiac surgery history

›Sex and genetic associations

›Genetic mutations

›HCN4 gene encoding pacemaker current If channel

›SCN5A gene encoding sodium channel Nav1.5

›Family history of congenital SSS

›Autosomal dominant inheritance in some kindreds

Pathophysiology

›Intrinsic causes

›Idiopathic degenerative fibrosis (most common)

›Progressive sinoatrial node replacement by fibrous tissue

›Age-dependent process

›Ischemic sinoatrial node disease

›Sinoatrial node artery from right coronary artery (60%) or left circumflex (40%)

›Sinoatrial node infarction with right coronary territory MI

›Infiltrative disease

›Amyloid deposition in conduction tissue

›Sarcoid granulomas in sinoatrial node

›Hemochromatosis iron deposition

›Inflammatory and autoimmune

›Myocarditis with sinoatrial node involvement

›Collagen vascular disease

›Chagas disease (T. cruzi) in endemic populations

›Extrinsic causes (reversible)

›Pharmacologic depression of sinoatrial node

›Beta blockers reduce automaticity via beta-1 receptor blockade

›CCBs (diltiazem, verapamil) depress sinoatrial node via calcium channel blockade

›Digoxin via vagotonic mechanism

›Metabolic and autonomic

›Hypothyroidism slows conduction and automaticity

›Hyperkalemia depolarizes resting membrane potential

›Obstructive sleep apnea: vagal surges during apnea events

›Electrophysiologic mechanism

›Sinoatrial node automaticity

›HCN4 channel mediates funny current If (pacemaker current)

›Spontaneous diastolic depolarization to threshold

›Sinoatrial conduction

›Exit block when impulse generated but not conducted to atria

›Manifest as grouped beating or dropped P waves on ECG

›Tachy-brady mechanism

›Abnormal sinoatrial node fails to recover automaticity after tachyarrhythmia termination

›Post-tachycardia pause due to overdrive suppression of diseased node

Therapeutic Considerations

›Pacemaker therapy evidence base

›Symptom improvement vs mortality

›Pacemakers reliably improve symptoms and quality of life

›No proven reduction in mortality in SSS specifically

›Atrial-based pacing reduces AF incidence vs ventricular-only pacing

›Pacing mode selection evidence

›AAI or DDD preferred over VVI (AFP, JACC guidelines)

›Dual-chamber pacing for suspected or confirmed AV conduction abnormalities

›Rate-responsive feature for chronotropic incompetence

›Tachy-brady treatment sequence

›Rate-control and antiarrhythmics worsen bradycardia without pacemaker

›Pacemaker must be implanted first

›Antiarrhythmics then initiated safely with pacing backup

›Anticoagulation for atrial fibrillation component

›Standard AF anticoagulation guidelines apply

›Thromboembolic risk elevated in SSS with AF

›Theophylline as alternative

›THEOPACE RCT (Circulation 1997)

›Oral theophylline vs permanent pacemaker in SSS

›Pacemaker superior for symptom control

›Theophylline reduced heart failure incidence vs pacemaker alone

›SORT rating C evidence for theophylline use

›Considered in patients refusing pacemaker

›Mechanism: phosphodiesterase inhibition increasing cAMP

›Natural history

›Progressive disease in most cases with intrinsic causes

›Tachy-brady syndrome develops in >= 50% of SSS patients

›Atrial fibrillation risk increases over time

›Reversible causes may fully resolve

›Medication-induced SSS: resolution after drug clearance

›Hypothyroidism: resolution with euthyroid state

11Patient Discharge Instructions/pdi43

copy discharge instructions

›Diagnosis and condition understanding

›Sick sinus syndrome is a condition where the heart's natural pacemaker does not work properly

›The heart rate may be too slow, too fast at times, or alternate between the two

›This can cause dizziness, fainting, fatigue, or palpitations

›The condition is usually progressive when due to natural aging of the heart's electrical system

›Treatment improves symptoms but may not cure the underlying cause

›Activity and safety instructions

›Do not drive until your cardiologist or electrophysiologist clears you

›Fainting while driving is dangerous

›Restrictions apply until syncope risk is addressed

›Avoid operating heavy machinery while at risk of fainting

›Discuss occupational safety with your doctor

›Moderate activity is generally safe if your heart rate is controlled

›Avoid strenuous exertion until cleared by specialist

›Medication instructions

›Take all prescribed medications as directed

›Do not stop or adjust heart medications without calling your doctor

›If a medication was stopped due to causing your slow heart rate, do not restart it

›If you have a pacemaker, carry your device identification card at all times

›Inform all healthcare providers and dentists that you have a pacemaker

›Avoid strong magnetic fields close to the device

›Follow-up instructions

›Cardiology or electrophysiology appointment within 1-2 weeks

›Heart monitor (Holter or event recorder) may be prescribed

›Wear monitor as directed and press button when symptoms occur

›Post-pacemaker follow-up at 2-4 weeks, then every 6-12 months

›Remote device monitoring may be available

12References/r44

Guidelines and key sources

›2018 ACC/AHA/HRS Guideline on Evaluation and Management of Patients with Bradycardia and Cardiac Conduction Delay

›Kusumoto FM, Schoenfeld MH, Barrett C, et al.

›Journal of the American College of Cardiology 2019

›Class I and IIa recommendations for pacemaker indications

›2012 ACCF/AHA/HRS Focused Update: Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities

›Epstein AE, DiMarco JP, Ellenbogen KA, et al.

›Journal of the American College of Cardiology 2013

›Pacemaker mode selection for SSS

›2021 PACES Expert Consensus Statement on CIEDs in Pediatric Patients

›Writing Committee Members, Silka MJ, Shah MJ, et al.

›Heart Rhythm 2021

›Pediatric pacemaker indications and management

Landmark trials and observational studies

›Jensen PN, Gronroos NN, Chen LY, et al.

›Incidence of and Risk Factors for Sick Sinus Syndrome in the General Population

›Journal of the American College of Cardiology 2014

›PMID 25104519

›Alboni P, Menozzi C, Brignole M, et al.

›THEOPACE Trial: Permanent Pacemaker and Oral Theophylline in SSS

›Circulation 1997

›PMID 9236443

›Kim HJ, Yang PS, Park H, et al.

›Comprehensive Risk Factor Analysis of Sick Sinus Syndrome (UK Biobank)

›Heart 2026

›PMID 41605626

Reviews and clinical summaries

›Hawks MK, Paul MLB, Malu OO.

Evidence & Review